Table I. Selected characteristics of patients* by initial radiotherapy treatment for first primary solid cancer, ages 20-84, 9 SEER registries, 1981-2007.
| Received initial radiotherapy | Did not receive initial radiotherapy | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||||
| Total patients diagnosed | Female | Patients who received initial radiotherapy | Mean age at diagnosis | Mean person-years at risk | Localized stage | Patients who did not receive initial radiotherapy | Mean age at diagnosis | Mean person-years at risk | Localized stage | |||
|
| ||||||||||||
| First primary cancer | N | % | N | % | Years | Years | % | N | % | Years | Years | % |
| All solid cancers | 1,450,962 | 49.4% | 481,163 | 33.2% | 70.5 | 5.4 | 50.8% | 969,799 | 66.8% | 70.0 | 6.4 | 62.8% |
| All standard radiotherapy treated solid cancers† | 982,404 | 51.4% | 417,217 | 42.5% | 72.3 | 5.7 | 55.7% | 565,187 | 57.5% | 72.6 | 6.8 | 66.1% |
| Oral cavity & pharynx | 42,667 | 31.4% | 24,212 | 56.7% | 68.6 | 4.6 | 20.7% | 18,455 | 43.3% | 69.3 | 6.9 | 67.0% |
| Larynx | 17,876 | 19.0% | 13,994 | 78.3% | 70.6 | 5.9 | 55.1% | 3,882 | 21.7% | 69.1 | 6.9 | 57.1% |
| Thyroid | 35,229 | 76.1% | 16,303 | 46.3% | 62.1 | 7.6 | 47.8% | 18,926 | 53.7% | 62.5 | 9.5 | 70.4% |
| Lung & bronchus (NSC) | 98,600 | 43.2% | 43,559 | 44.2% | 71.0 | 2.0 | 14.2% | 55,041 | 55.8% | 72.4 | 4.1 | 50.2% |
| Female breast | 310,719 | 100.0% | 138,499 | 44.6% | 69.6 | 6.5 | 63.1% | 172,220 | 55.4% | 71.9 | 7.7 | 60.3% |
| Cervix uteri | 22,820 | 100.0% | 10,794 | 47.3% | 67.0 | 6.5 | 29.9% | 12,026 | 52.7% | 59.9 | 10.7 | 84.3% |
| Endometrium | 60,767 | 100.0% | 20,216 | 33.3% | 71.9 | 7.6 | 61.6% | 40,551 | 66.7% | 71.3 | 8.2 | 86.9% |
| Prostate | 320,656 | 0.0% | 121,490 | 37.9% | 75.6 | 5.6 | 75.2% | 199,166 | 62.1% | 74.5 | 5.9 | 71.0% |
| Testis | 15,356 | 0.0% | 6,973 | 45.4% | 53.2 | 10.8 | 83.4% | 8,383 | 54.6% | 50.6 | 10.4 | 59.2% |
| Rectum & rectosigmoid junction | 57,714 | 42.5% | 21,177 | 36.7% | 72.1 | 4.9 | 25.9% | 36,537 | 63.3% | 73.9 | 6.0 | 62.1% |
Abbreviations: NSC, non-small cell
*
Study population was restricted to first prim ary cance r diagnosed betwee n ages 20-84 and survival at least one y ear followin g diagnosis .
Cohort follow-up was censored at age 85 years due to under-ascertainment of second cancers among older patients.
†
Includes oral cavity & pharynx, rectosigmoid junction & rectum, larynx, lung & bronchus (NSC), female breast, cervix uteri, en dometrial, prostate, testis, and thyroid cancers.